Drug development

North America Cell-based Assays Market Report 2022: Featuring Becton, Dickinson, Bio-Rad Laboratories, Danaher, F. Hoffmann-La Roche & More - ResearchAndMarkets.com

Retrieved on: 
Friday, January 13, 2023

The "North America Cell-based Assays Market Size, Share & Industry Trends Analysis Report by Application (Drug Discovery, Basic Research and Others), End-user, Products & Services, Country and Growth Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America Cell-based Assays Market Size, Share & Industry Trends Analysis Report by Application (Drug Discovery, Basic Research and Others), End-user, Products & Services, Country and Growth Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • These assays include cell viability assays, cell proliferation assays, and GPCR assays.
  • These high-throughput assays speed up the process of drug discovery by giving the most promising candidate in the biological context that matters the most.
  • The US market dominated the North America Cell-based Assays Market by Country in 2021; thereby, achieving a market value of $7.2 billion by 2028.

Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole

Retrieved on: 
Friday, January 13, 2023

Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance of new patent claims for ATI-1501 , Appili’s liquid oral reformulation of the antibiotic metronidazole.

Key Points: 
  • Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance of new patent claims for ATI-1501 , Appili’s liquid oral reformulation of the antibiotic metronidazole.
  • A notice of allowance is issued by the USPTO to indicate that the application has passed the examination.
  • Metronidazole is a widely used frontline oral treatment with over 10 million prescriptions written in the United States every year to help treat parasitic and anaerobic bacterial infections.
  • “We are pleased with this notice of allowance for a new patent that will further strengthen ATI-1501’s potential as a more convenient antibiotic treatment option,” said Don Cilla, Pharm.D., M.B.A., President and Chief Executive Officer of Appili Therapeutics.

Simulations Plus Releases DILIsym X (DSX) Beta with Redesigned Software Infrastructure

Retrieved on: 
Thursday, January 12, 2023

Simulations Plus , Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services (DSS) division has released DILIsym® version X (DSX) Beta, the latest version of its flagship quantitative systems toxicology (QST) software for predicting and investigating drug-induced liver injury (DILI).

Key Points: 
  • Simulations Plus , Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services (DSS) division has released DILIsym® version X (DSX) Beta, the latest version of its flagship quantitative systems toxicology (QST) software for predicting and investigating drug-induced liver injury (DILI).
  • DSX represents a great advance in that it simplifies the use of the software and greatly increases the speed with which it provides results.
  • This will enable much wider adoption of the software by Pharma, regulators, and academics.”
    Dr. Brett Howell , president of the DILIsym Services division, added: “DILIsym is increasingly being used for high impact applications in the safety space.
  • For the past 12 years, the DILIsym Services division has coordinated the DILI-sim Initiative, which is a public-private partnership that has guided development of the DILIsym software package.

Outlook on the RNA Analysis Global Market to 2028 - Featuring Illumina, Bio-Rad Laboratories, Eurofins Scientific and Merck Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023

The Global RNA Analysis Market size is expected to reach $28 billion by 2028, rising at a market growth of 15.6% CAGR during the forecast period.

Key Points: 
  • The Global RNA Analysis Market size is expected to reach $28 billion by 2028, rising at a market growth of 15.6% CAGR during the forecast period.
  • The method used to produce RNA in a lab setting from a DNA template is known as in vitro transcription.
  • For use in procedures like in vitro translation, the investigation of RNA viruses, and RNA: protein interaction investigations, RNA is produced from DNA templates using in vitro transcription devices.
  • For use in RNA analysis research, single-stranded RNA probes, microgram amounts of specified RNA transcripts, and antisense RNA are all prepared using riboprobe systems.

MMS Named a Great Place to Work in India

Retrieved on: 
Thursday, January 12, 2023

MMS Holdings, a data-focused contract research organization (CRO), has been named a Great Place to Work by the Great Place to Work Institute of India.

Key Points: 
  • MMS Holdings, a data-focused contract research organization (CRO), has been named a Great Place to Work by the Great Place to Work Institute of India.
  • Over 87% of MMS employees completed the survey, and based on their feedback, MMS was recognized as demonstrating the excellent workplace culture needed for success.
  • “We are honored to be named a Great Place to Work in India, especially because our colleagues determined the result,” said Uma Sharma , Ph.D., Chief Executive Officer at MMS.
  • With a global footprint across four continents, including offices in Bangalore and Hyderabad, MMS maintains one of the highest retention rates in the industry.

Global Hormone Replacement Therapy Market 2022: A $25+ Billion Market by 2027 - Industry Trends, Growth, Impact of Inflation, Opportunities, Company Analysis - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023

The "Hormone Replacement Therapy Market, Global Forecast 2023-2027, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hormone Replacement Therapy Market, Global Forecast 2023-2027, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Global Hormone Replacement Therapy Market is expected to reach US$ 25.09 Billion by 2027 from US$ 18.04 Billion in 2022, growing with a CAGR of 6.82% during 2022-2027.
  • According to the UN, the global population will grow by 8.5 billion in 2030 and 9.7 billion in 2050.
  • Based on Type, hormone replacement therapy is categorized into Estrogen, Human Growth, Thyroid, Testosterone, and Progestogen.

Global eClinical solutions Market Report 2022 to 2028: Rising Adoption of Software Solutions in Clinical Trails Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 10, 2023

The Global eClinical solutions Market size is expected to reach $20.1 billion by 2028, rising at a market growth of 13.6% CAGR during the forecast period.

Key Points: 
  • The Global eClinical solutions Market size is expected to reach $20.1 billion by 2028, rising at a market growth of 13.6% CAGR during the forecast period.
  • With professional data services as well as the elluminate Clinical Data Cloud, eClinical Solutions assists life sciences enterprises all over the world in accelerating clinical development projects.
  • The eClinical solutions market is concentrating on the development and marketing of software solutions that help speed up and efficiently complete clinical studies.
  • Many integrated eClinical solutions (like CTMS and CDMS) offer clinical researchers end-to-end solutions for all phases of clinical trial administration.

Global Lysosomal Disease Treatment Market Report 2022 to 2028: Featuring Pfizer, Takeda Pharmaceutical, Sanofi and Novartis Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 10, 2023

The Global Lysosomal Disease Treatment Market size is expected to reach $11 billion by 2028, rising at a market growth of 6.3% CAGR during the forecast period.

Key Points: 
  • The Global Lysosomal Disease Treatment Market size is expected to reach $11 billion by 2028, rising at a market growth of 6.3% CAGR during the forecast period.
  • Lysosomal diseases (LSDs) are a complex group of metabolic disorders that are often inherited in an autosomal recessive manner.
  • The primary driving forces in the enzyme replacement therapy market are the expanding research and development for lysosomal disease diagnosis and drug development for treatment.
  • The increasing incidence of lysosomal disease will be a key factor contributing to the acceleration of the market's growth rate.

Global Small Molecule Contract Development and Manufacturing Organization Market Report 2023: Increased Demand for Small Molecule Medicines Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 10, 2023

The "Global Small Molecule Contract Development and Manufacturing Organization Market 2021-2031 by Product Type, Service Type, Customer Type, Therapeutic Area, and Region: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Small Molecule Contract Development and Manufacturing Organization Market 2021-2031 by Product Type, Service Type, Customer Type, Therapeutic Area, and Region: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.
  • Global small molecule contract development and manufacturing organization (CDMO) market will reach $117,920.3 million by 2031, growing by 6.4% annually over 2021-2031, driven by the increasing demand for small molecule medicines and therapies, a rising demand for cost control in drug development, the increasing incidence of disease, and rising healthcare expenditures.
  • This 166-page report is based on a comprehensive research of the entire global small molecule contract development and manufacturing organization (CDMO) market and all its sub-segments through extensively detailed classifications.
  • The report is based on studies on 2019-2021 and provides forecast from 2022 till 2031 with 2021 as the base year.

CRISPR QC Closes Seed Round at $1.6M and Appoints George Bonaros to Board of Directors to Fuel Commercial Growth of Their CRISPR Analytics Platform

Retrieved on: 
Tuesday, January 10, 2023

On January 9th 2023, CRISPR QC has announced that they have closed their Seed Round at $1.6M and appoints George Bonaros to Board of Directors to fuel commercial growth of their CRISPR Analytics Platform.

Key Points: 
  • On January 9th 2023, CRISPR QC has announced that they have closed their Seed Round at $1.6M and appoints George Bonaros to Board of Directors to fuel commercial growth of their CRISPR Analytics Platform.
  • CRISPR QC’s CRISPR Analytics Platform provides new dimensions of data and analytics to CRISPR gene editing that allows their partners to accelerate product development.
  • The seed round funding is being invested to advance commercial development of the CRISPR Analytics Platform and to further enhance data analytics capabilities.
  • At CRISPR QC we utilize our CRISPR Analytics Platform, powered by the CRISPR-Chip™, to optimize and de-risk gene editing outcomes by providing a new form of insight into CRISPR.